Chris Cabell, M.D., is senior vice president and head of the Therapeutic & Specialty Business Development team within the Customer Solutions Management Group (CSMG). With oversight of regional and functional clinical development sales and the Therapeutic Centers of Excellence, Cabell is responsible for leveraging our deep therapeutic expertise across all of our core customer segments to strengthen our selling approach and engage our customers earlier in the sales process.
Prior to assuming this role in November 2014, Cabell was head of the Therapeutic Delivery Unit for Quintiles, responsible for developing clinical and business strategies to deliver Phase II-III clinical trials evaluating vaccines, drugs and therapies targeting hundreds of diseases. Cabell joined Quintiles in 2007 as the cardiovascular/endocrine global therapeutic group leader and has held numerous roles at the company, including chief medical and scientific officer and senior vice president of Global Access to Patients.
Board certified in both internal medicine and cardiovascular diseases, Cabell is an honors graduate of The Pennsylvania State University and Duke University, earning both his medical degree and a Masters in Health Sciences from the latter. He is also a Fellow of the American College of Cardiology. Cabell has more than 100 peer-reviewed publications and has published in prestigious journals, including New England Journal of Medicine, JAMA, and Annals of Internal Medicine.